Results 161 to 170 of about 462,808 (314)

Correction: Melanoma toolkit for early detection for primary care clinicians: a 1-year follow-up on outcomes. [PDF]

Front Med (Lausanne)
Diehl K, Stoos E, Becker A, Orfaly VE, Nelson J, Gillespie J, Ng J, Tobey T, Latour E, Ludzik J, Berry EG, Geller AC, Jacobe H, Leitenberger J, McClanahan D, Tran J, Prasad S, Mengden-Koon S, Nelson KC, Petering R, Verdieck A, Savory S, Smith EH, Tofte S, Weinstock MA, White K, Wisco O, Curiel-Lewandrowski C, Swetter SM, Witkowski AM, Ferris L, Black S, Xu R, Xu S, Leachman S.   +34 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Vol. 24 No. 1 (2026): Nepal Journal of Dermatology, Venereology & Leprology

Nepal Journal of Dermatology, Venereology & Leprology
Table of Content ...
Nepal Journal of Dermatology, Venereology and Leprosy
doaj  

Assessing the Utility of a Cosmetic Dermatology Journal Club. [PDF]

J Cosmet Dermatol
Chang J, Alvi S, Zhang E, Smith SS, Gullapalli T, Lazaro-Camp VJ, Dragovic D, Ahmed A, Carter DC, Mills DE, Henderson AA, El-Khateeb H, Kang BY, Alam M.   +13 more
europepmc   +1 more source

Preserving Dermatology [PDF]

Journal of Investigative Dermatology, 2013
Moy, Ron, Antunes, Humberto C.
openaire   +2 more sources

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source

Age-related histopathological and immunophenotypic variations in early-stage mycosis fungoides: a multicentre retrospective study in Türkiye. [PDF]

BMJ Open
Solak B, Çakırsoy Çakar G, Güngör Z, Gezmen S, Karabulut YY, Demirseren DD, Orhun HS, Gönülal Bak R, Karstarli Bakay OS, Çomut E, Taş Aygar G, Gökce A, Canpolat F, Kahraman FC, Çobanoğlu B, Akbulak Ö, Aksu A, Kaya HE, Altınel D, Zorlu Ö, Karabağ S, Yazici S, Adim SB, Demirbaş A, Bayramgurler D, Yaprak Bayrak B, Esen M, Sula B, İbiloğlu İ, Baştuğ D, Kuşku Çabuk F, Caf N, Temiz SA, Daye M, Kılınç F, Çelik A, Türsen Ü.   +36 more
europepmc   +1 more source

Clinical Images: Subcutaneous panniculitis‐like T cell lymphoma

Arthritis &Rheumatology, EarlyView.
S Chambers, CN Myrdal, VP Werth
wiley   +1 more source

Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults

British Journal of Clinical Pharmacology, EarlyView.
Aim To evaluate the effects of carbamazepine, a strong cytochrome P450 (CYP)3A4 inducer, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader. Methods This was a phase 1, open‐label, fixed‐sequence, two‐period study in healthy adult participants.
Hechuan Wang, Jennifer A. Winton, Kyle T. Matschke, Alexandre Stouffs, Kimberly C. Lee, Yuanyuan Zhang, Wenlian Qiao, Weiwei Tan   +7 more
wiley   +1 more source

Correction: Oregon primary care providers as a frontline defense in the War on Melanoma™: improving access to melanoma education. [PDF]

Front Med (Lausanne)
Becker AL, Nelson JH, Verdieck-Devlaeminck A, Berry EG, Orfaly VE, Stoos ER, Tran J, Latour E, Sahni VN, Xu S, Babcock M, Bar A, Becevic M, Chan C, Chisholm D, Diehl K, Edison K, Ferris LK, Foltz EA, Geller AC, Jacobe H, Johnson MM, Kinghorn P, Leitenberger J, Ludzik J, McClanahan D, Mengden-Koon S, Nelson K, Petering R, Prasad S, Roscher A, Savory S, Smith EH, Swetter SM, Tofte S, Weinstock MA, White K, Wisco O, Witkowski A, Leachman SA.   +39 more
europepmc   +1 more source